Method for the treatment of cancer via tumor cell lysis and intratumoral administration of combinations of immunotherapeutic ingredients

A pharmaceutical composition comprising:

• a. a TLR9 agonist;
• b. an agonistic anti-CD40 monoclonal antibody;
• c. an anti-CTLA4 monoclonal antibody;
• d. an agonistic anti-OX40 monoclonal antibody;
• and
• e. pharmaceutical acceptable excipients.

A pharmaceutical composition comprising:

• a. a TLR9 agonist;
• b. an agonistic anti-CD40 monoclonal antibody;
• c. an anti-CTLA4 monoclonal antibody;
• d. an agonistic anti-PD1 monoclonal antibody;
• and
• e. pharmaceutical acceptable excipients.

A method of treating cancer in a subject, the method comprising steps of:

• a) administering to a tumor in the subject a cryolysis therapy that causes partial tumor cell lysis;
• and
• b) administering to the same tumor in step a) a therapeutically effective amount of a combination formulation,
• wherein the combination formulation comprises:
• a. a TLR9 agonist;
• b. an agonistic anti-CD40 monoclonal antibody;
• c. an anti-CTLA4 monoclonal antibody;
• and
• d. an agonistic anti-OX40 monoclonal antibody;
• wherein the cryolysis therapy is administered prior to administration of the combination formulation.

A method of treating cancer in a subject, the method comprising steps of:

• a) administering to a tumor in the subject a cryolysis therapy that causes partial tumor cell lysis;
• and
• b) administering to the same tumor in step a) a therapeutically effective amount of a combination formulation,
• wherein the combination formulation comprises:
• a. a TLR9 agonist;
• b. an agonistic anti-CD40 monoclonal antibody;
• c. an anti-CTLA4 monoclonal antibody;
• and
• d. an anti-PD1 monoclonal antibody;
• wherein the cryolysis therapy is administered prior to administration of the combination formulation.